Ptc Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
Ptc Therapeutics (US): 2 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $218.1M 2024 CMS Part D & Medicaid spend, and 10 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 2 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 100.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $218.1M |
| 2024 Medicare Part D Spend | $15.4M |
| 2024 Medicaid Spend | $202.7M |
| California HCAI SB 17 Filings | 10 WAC filings (max 76.6% 2-yr change) |